1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: A pooled analysis of the ABSORB and the SPIRIT trials

JACC: Cardiovascular Interventions

Volumn 7, Issue 5, 2014, Pages 482-493

  Muramatsu, Takashi ^a,b   Onuma, Yoshinobu ^a   Van Geuns, Robert Jan ^a   Chevalier, Bernard ^c   Patel, Tejas M ^d   Seth, Ashok ^e   Diletti, Roberto ^a   García García, Hector M ^a   Dorange, Cécile C ^f   Veldhof, Susan ^f   Cheong, Wai Fung ^f   Ozaki, Yukio ^b   Whitbourn, Robert ^g   Bartorelli, Antonio ^h   Stone, Gregg W ⁱ   Abizaid, Alexandre ^j   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^c INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^d Krishna Heart Institute   (India)

^e ESCORTS HEART INSTITUTE AND RESEARCH CENTRE   (India)

^f ABBOTT VASCULAR   (United States)

^g ST VINCENT S HOSPITAL   (Australia)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ NewYork Presbyterian Hospital   (United States)

^j INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

more..

Author keywords

bioresorbable scaffold; coronary artery disease; diabetes mellitus; drug eluting stent

Indexed keywords

ADULT; ARTICLE; BIORESORBABLE VASCULAR STENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METAL STENT; PRIORITY JOURNAL; REVASCULARIZATION; STENT THROMBOSIS; TREATMENT OUTCOME; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; DIABETIC PATIENT; FAMILY HISTORY; HEART DISEASE; HEART MUSCLE REVASCULARIZATION; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INSULIN TREATMENT; LOADING DRUG DOSE; OUTCOME ASSESSMENT; UNSTABLE ANGINA PECTORIS; AGED; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CORONARY STENOSIS; CORONARY THROMBOSIS; DIABETIC ANGIOPATHIES; KAPLAN MEIER METHOD; META ANALYSIS; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROSTHESIS; RISK FACTOR; TIME;

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; CREATINE KINASE MB; EVEROLIMUS; INSULIN; ORAL ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; RAPAMYCIN;

ABSORBABLE IMPLANTS; AGED; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS AS TOPIC; CORONARY STENOSIS; CORONARY THROMBOSIS; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROSTHESIS DESIGN; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901269957     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.01.155     Document Type: Article

References (37)

1. P. Zimmet, K.G. Alberti, and J. Shaw Global and societal implications of the diabetes epidemic Nature 414 2001 782 787
2. J. Stamler, O. Vaccaro, J.D. Neaton, and D. Wentworth Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
3. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
4. C. Stettler, S. Allemann, and S. Wandel et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis BMJ 337 2008 a1331
5. E. Van Belle, M. Perie, and D. Braune et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients J Am Coll Cardiol 40 2002 410 417
6. V. Mathew, and D.R. Holmes Outcomes in diabetics undergoing revascularization: the long and the short of it J Am Coll Cardiol 40 2002 424 427
7. G.W. Stone, M. Midei, and W. Newman et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913
8. G.W. Stone, A. Rizvi, and W. Newman et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
9. P.W. Serruys, V. Farooq, and B. Kalesan et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial J Am Coll Cardiol Intv 6 2013 777 789
10. G.W. Stone, E. Kedhi, and D.J. Kereiakes et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus Circulation 124 2011 893 900
11. Y. Onuma, and P.W. Serruys Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 123 2011 779 797
12. P.W. Serruys, Y. Onuma, and H.M. Garcia-Garcia et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months EuroIntervention 2013 Dec 3 [E-pub ahead of print]
13. P.W. Serruys, Y. Onuma, and D. Dudek et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes J Am Coll Cardiol 58 2011 1578 1588
14. T. Muramatsu, Y. Onuma, and H.M. Garcia-Garcia et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT First and II trials J Am Coll Cardiol Intv 6 2013 247 257
15. P.W. Serruys, A.T. Ong, and J.J. Piek et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial EuroIntervention 1 2005 58 65
16. P.W. Serruys, P. Ruygrok, and J. Neuzner et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 2006 286 294
17. D.E. Cutlip, S. Windecker, and R. Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
18. P. Vranckx, D.E. Cutlip, and R. Mehran et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies EuroIntervention 5 2010 871 874
19. R. Kornowski, G.S. Mintz, and K.M. Kent et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study Circulation 95 1997 1366 1369
20. I. Iakovou, T. Schmidt, and E. Bonizzoni et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
21. M.E. Farkouh, M. Domanski, and L.A. Sleeper et al. Strategies for multivessel revascularization in patients with diabetes N Engl J Med 367 2012 2375 2384
22. P.W. Serruys, and V. Farooq Revascularization strategies in patients with diabetes N Engl J Med 368 2013 1454 1455
23. W. Wijns, P. Kolh, and N. Danchin et al. Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
24. G.N. Levine, E.R. Bates, J.C. Blankenship American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 122
25. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 2007 1440 1455 discussion 1455
26. W.H. Maisel Unanswered questions-drug-eluting stents and the risk of late thrombosis N Engl J Med 356 2007 981 984
27. C. Spaulding, J. Daemen, E. Boersma, D.E. Cutlip, and P.W. Serruys A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 2007 989 997
28. W.J. Kim, S.W. Lee, and S.W. Park et al. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial Circulation 124 2011 886 892
29. T. Kimura, T. Morimoto, and M. Natsuaki et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET) Circulation 126 2012 1225 1236
30. K.E. Bornfeldt, E.W. Raines, T. Nakano, L.M. Graves, E.G. Krebs, and R. Ross Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation J Clin Invest 93 1994 1266 1274
31. P. Rocic Differential phosphoinositide 3-kinase signaling: implications for PTCA? Am J Physiol Heart Circ Physiol 297 2009 H1970 H1971
32. S. Silber, S. Windecker, P. Vranckx, and P.W. Serruys Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247
33. L. Ryden, E. Standl, and M. Bartnik et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136
34. J.A. Ormiston, P.W. Serruys, and Y. Onuma et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study Circ Cardiovasc Interv 5 2012 620 632
35. B.E. Claessen, M.A. Beijk, and V. Legrand et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial Circ Cardiovasc Interv 2 2009 339 347
36. P.W. Serruys, H.M. Garcia-Garcia, and Y. Onuma From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 33 2012 16 25b
37. T. Muramatsu, Y. Onuma, and Y.J. Zhang et al. Progress in treatment by percutaneous coronary intervention: the stent of the future Rev Esp Cardiol 66 2013 483 496